研究氨磺必利与利培酮治疗首发精神分裂症的临床疗效
|
摘要
目的对比氨磺必利与利培酮治疗首发精神分裂症的临床疗效。方法选取焦作市第四人民医院2016年3月至2017年3月收治的60例首发精神分裂症作为研究对象,按照入院顺序,单号分为研究组(n=30),双号作为对照组(n=30),其中对照组患者采用利培酮进行治疗,研究组患者采用氨磺必利药物进行治疗,对比两组患者的临床疗效,同时客观评估两组患者治疗前后的阴性与阳性症状量表(PANSS)。结果经比较,研究组和对照组患者的临床总有效率分别为76.67%和66.66%,差异无统计学意义(P>0.05);研究组患者治疗后2周、4周和8周的PANSS量表评分优于对照组和治疗前,但P>0.05,不具有统计学意义。结论氨磺必利与利培酮治疗首发精神分裂症的临床疗效相当,但是氨磺必利对患者的阴性症状和抑郁症状的改善情况更好。
Objective To investigate the clinic effect of amisulpride and risperidone in treatment of first episode schizophrenic patients. Methods 60 cases with first episode schizophrenic in The Fourth People's Hospital of Jiaozuo from March 2016 to March 2017 were selected and divided into observation group(n=30) and control group(n=30), According to the admission order, the single number is divided into the study group(n=30), and the double number is the control group(n=30), clinic effect of the two groups was compared and PANSS of the two groups before and after treatment was objectively evaluated. Results After comparison, The total clinical efficiency of the study group and the control group was 76.67% and 66.66%, respectively, with no statistically significant difference(P>0.05). 2, 4 8 weeks after treatment, PANSS score of study group was better than control group and that before treatment,but P>0.05 was not statistically significant. Conclusion Amisulpride and risperidone has same clinic effect on treatment of first episode schizophrenic patients, but amisulpride can improve negative symptoms and depressive symptoms better.
Objective To investigate the clinic effect of amisulpride and risperidone in treatment of first episode schizophrenic patients. Methods 60 cases with first episode schizophrenic in The Fourth People's Hospital of Jiaozuo from March 2016 to March 2017 were selected and divided into observation group(n=30) and control group(n=30), According to the admission order, the single number is divided into the study group(n=30), and the double number is the control group(n=30), clinic effect of the two groups was compared and PANSS of the two groups before and after treatment was objectively evaluated. Results After comparison, The total clinical efficiency of the study group and the control group was 76.67% and 66.66%, respectively, with no statistically significant difference(P>0.05). 2, 4 8 weeks after treatment, PANSS score of study group was better than control group and that before treatment,but P>0.05 was not statistically significant. Conclusion Amisulpride and risperidone has same clinic effect on treatment of first episode schizophrenic patients, but amisulpride can improve negative symptoms and depressive symptoms better.
引文
[1]孙国英,易正辉,张艳欣,等.家庭治疗对精神分裂症患者的疗效及家庭功能的影响[J].国际精神病学杂志,2015(2):35-38.
[2]Gupta S,Jain S,Brahmachari S K,et a l.Pharmacogenomics:Apathto predictive medicine for schizophrenia[J].Pharmacogenomics,2016,7(1):31-47.
[3]曹民佑,杨建明,高永双.帕利哌酮缓释剂对慢性精神分裂症阴性症状及社会功能的影响[J].中国实用医药,2015(15):155-157.
[4]李新峰.齐拉西酮对精神分裂症患者执行功能、述情障碍的远期影响[J].国际精神病学杂志,2016(3):396-398.
[5]李长明,陈文胜.帕利哌酮缓释片与利培酮片对首发精神分裂症疗效及安全性分析[J].海峡药学,2015(7):99-100.
[6]江开达.第二代抗精神病药在双相障碍躁狂发作中的应用[J].中华精神科杂志,2012,45(5):309-310.
[7]张云淑,司天梅,栗克清.中国十省市第一代及第二代抗精神病药使用现况调查[J].中国心理卫生杂志,2012,26(10):736-[J].中国740.
[2]Gupta S,Jain S,Brahmachari S K,et a l.Pharmacogenomics:Apathto predictive medicine for schizophrenia[J].Pharmacogenomics,2016,7(1):31-47.
[3]曹民佑,杨建明,高永双.帕利哌酮缓释剂对慢性精神分裂症阴性症状及社会功能的影响[J].中国实用医药,2015(15):155-157.
[4]李新峰.齐拉西酮对精神分裂症患者执行功能、述情障碍的远期影响[J].国际精神病学杂志,2016(3):396-398.
[5]李长明,陈文胜.帕利哌酮缓释片与利培酮片对首发精神分裂症疗效及安全性分析[J].海峡药学,2015(7):99-100.
[6]江开达.第二代抗精神病药在双相障碍躁狂发作中的应用[J].中华精神科杂志,2012,45(5):309-310.
[7]张云淑,司天梅,栗克清.中国十省市第一代及第二代抗精神病药使用现况调查[J].中国心理卫生杂志,2012,26(10):736-[J].中国740.